A BILL 
To direct the Secretary of Health and Human Services to 
support research on, and expanded access to, investiga-
tional drugs for amyotrophic lateral sclerosis, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Accelerating Access 
4
to Critical Therapies for ALS Act’’. 
5
SEC. 2. GRANTS FOR RESEARCH ON THERAPIES FOR ALS. 
6
(a) IN GENERAL.—The Secretary of Health and 
7
Human Services (referred to in this section as the Sec-
8
retary) shall award grants to participating entities for pur-
9
poses of expanded access for individuals to investigational 
10
drugs for the prevention, diagnosis, mitigation, treatment, 
11
or cure of amyotrophic lateral sclerosis. In the case of an 
12
applicant seeking such a grant, an expanded access re-
13
quest must be submitted, and allowed to proceed by the 
14
Secretary, under section 561 of the Federal Food, Drug, 
15
and Cosmetic Act (21 U.S.C. 360bbb) and part 312 of 
16
title 21, Code of Federal Regulations (or any successor 
17
regulations), before the application for such grant is sub-
18
mitted. 
19
(b) APPLICATION.— 
20
22:46 Jun 23, 2021
H3537
3 
•HR 3537 IH
(1) IN GENERAL.—A participating entity seek-
1
ing a grant under this section shall submit to the 
2
Secretary an application at such time, in such man-
3
ner, and containing such information as the Sec-
4
retary shall specify. 
5
(2) USE OF DATA.—An application submitted 
6
under paragraph (1) shall include a description of 
7
how data generated through an expanded access re-
8
quest under section 561 of the Federal Food, Drug, 
9
and Cosmetic Act (21 U.S.C. 360bbb) with respect 
10
to the investigational drug involved may be used by 
11
the Secretary to support research or development re-
12
lated to the prevention, diagnosis, mitigation, treat-
13
ment, or cure of amyotrophic lateral sclerosis or 
14
other rare neurodegenerative diseases. 
15
(c) SELECTION.—Not later than 120 days after the 
16
date of submission of an application for a grant under this 
17
section, the Secretary shall determine whether to award 
18
the grant, taking into consideration— 
19
(1) whether awarding such grant will support a 
20
research objective relating to expanding access to in-
21
vestigational drugs (as described in subsection (a)); 
22
and 
23
22:46 Jun 23, 2021
H3537
4 
•HR 3537 IH
(2) whether awarding such a grant may have 
1
the effect of diminishing eligibility for, or impeding 
2
enrollment of, ongoing clinical investigations. 
3
(d) USE OF FUNDS.—A participating entity may use 
4
funds received through the grant— 
5
(1) to pay the manufacturer or sponsor for the 
6
direct costs of such drug (as authorized under sec-
7
tion 312.8(d) of title 21, Code of Federal Regula-
8
tions (or successor regulations)), if such costs are 
9
justified as part of peer review of the grant; 
10
(2) for the entity’s direct costs incurred in pro-
11
viding such drug consistent with the research mis-
12
sion of the grant; or 
13
(3) for the direct and indirect costs of the enti-
14
ty in conducting research with respect to the drug 
15
involved. 
16
(e) DEFINITIONS.—In this section: 
17
(1) The term ‘‘participating entity’’ means a 
18
participating clinical trial site or sites sponsored by 
19
a small business concern (as defined in section 3(a) 
20
of the Small Business Act (15 U.S.C. 632(a)) that 
21
is the sponsor of a drug that is the subject of an in-
22
vestigational new drug application under section 
23
505(i) of the Federal Food, Drug, and Cosmetic Act 
24
(21 U.S.C. 355(i)). 
25
22:46 Jun 23, 2021
H3537
5 
•HR 3537 IH
(2) The term ‘‘participating clinical trial’’ 
1
means a phase 3 clinical trial conducted pursuant to 
2
an exemption under section 505(i) of the Federal 
3
Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) or 
4
section 351(a) of the Public Health Service Act (42 
5
U.S.C. 262(a)) to investigate a drug intended to pre-
6
vent, diagnose, mitigate, treat, or cure amyotrophic 
7
lateral sclerosis. 
8
(3) The term ‘‘participating clinical trial site’’ 
9
means a nonprofit or public health care facility, or 
10
network of facilities, at which patients participating 
11
in a participating clinical trial receive an investiga-
12
tional drug through such trial. 
13
SEC. 3. HHS PUBLIC-PRIVATE PARTNERSHIP FOR RARE 
14
NEURODEGENERATIVE DISEASES. 
15
(a) ESTABLISHMENT.—Not later than one year after 
16
the date of enactment of this Act, the Secretary of Health 
17
and Human Services (referred to in this section as the 
18
‘‘Secretary’’) shall establish and implement a Public-Pri-
19
vate Partnership for Neurodegenerative Diseases between 
20
the National Institutes of Health, the Food and Drug Ad-
21
ministration, and one or more eligible entities (to be 
22
known and referred to in this section as the ‘‘Partner-
23
ship’’) through cooperative agreements, contracts, or other 
24
appropriate instruments with such eligible entities, for the 
25
22:46 Jun 23, 2021
H3537
6 
•HR 3537 IH
purpose of developing treatments for amytrophic lateral 
1
sclerosis and other rare neurodegenerative diseases. The 
2
Partnership shall— 
3
(1) establish partnerships, consortia, and col-
4
laborations with other public and private entities 
5
and individuals with expertise in amyotrophic lateral 
6
sclerosis and other rare neurodegenerative diseases 
7
for the purposes described in this subsection; 
8
(2) focus on advancing regulatory science and 
9
scientific research that will support and accelerate 
10
the development and review of drugs for patients 
11
with amyotrophic lateral sclerosis and other rare 
12
neurodegenerative diseases; and 
13
(3) foster the development of effective drugs 
14
that improve the lives of people that suffer from 
15
amyotrophic 
lateral 
sclerosis 
and 
other 
rare 
16
neurodegenerative diseases. 
17
(b) ELIGIBLE ENTITY.—In this section, the term ‘‘el-
18
igible entity’’ means an entity that— 
19
(1) is— 
20
(A) an institution of higher education (as 
21
such term is defined in section 1001 of the 
22
Higher Education Act of 1965 (20 U.S.C. 
23
1001)) or a consortium of such institutions; or 
24
22:46 Jun 23, 2021
H3537
7 
•HR 3537 IH
(B) an organization described in section 
1
501(c)(3) of the Internal Revenue Code of 1986 
2
and exempt from tax under subsection (a) of 
3
such section; 
4
(2) has experienced personnel and demonstrated 
5
connection to the patient population; 
6
(3) demonstrates to the Secretary’s satisfaction 
7
that the entity is capable of identifying and estab-
8
lishing collaborations between public and private en-
9
tities 
and 
individuals 
with 
expertise 
in 
10
neurodegenerative diseases, including patients, in 
11
order to facilitate— 
12
(A) development and critical evaluation of 
13
tools, methods, and processes— 
14
(i) to characterize neurodegenerative 
15
diseases and their natural history; 
16
(ii) to identify drug targets for 
17
neurodegenerative diseases; and 
18
(iii) to increase efficiency, predict-
19
ability, and productivity of clinical develop-
20
ment of therapies, including advancement 
21
of rational therapeutic development and es-
22
tablishment of clinical trial networks; and 
23
(B) securing funding for the Partnership 
24
from Federal and non-Federal governmental 
25
22:46 Jun 23, 2021
H3537
8 
•HR 3537 IH
sources, foundations, and private individuals; 
1
and 
2
(4) provides an assurance that the entity will 
3
not accept funding for a Partnership project from 
4
any organization that manufactures or distributes 
5
products regulated by the Food and Drug Adminis-
6
tration unless the entity provides assurances in its 
7
agreement with the Secretary that the results of the 
8
project will not be influenced by any source of fund-
9
ing. 
10
(c) GIFTS.— 
11
(1) IN GENERAL.—The Partnership may solicit 
12
and accept gifts, grants, and other donations, estab-
13
lish accounts, and invest and expend funds in sup-
14
port of pre-competitive research and research associ-
15
ated with phase 3 clinical trials conducted with re-
16
spect to investigational drugs that are the subjects 
17
of expanded access applications under section 561 of 
18
the Federal Food, Drug, and Cosmetic Act (21 
19
U.S.C. 360bbb). 
20
(2) USE.—In addition to any amounts appro-
21
priated for purposes of carrying out this section, the 
22
Partnership may use, without further appropriation, 
23
any funds derived from a gift, grant, or other dona-
24
tion accepted pursuant to paragraph (1). 
25
22:46 Jun 23, 2021
H3537
9 
•HR 3537 IH
SEC. 4. ALS AND OTHER RARE NEURODEGENERATIVE DIS-
1
EASE ACTION PLAN. 
2
(a) IN GENERAL.—Not later than 6 months after the 
3
date of enactment of this Act, the Secretary of Health and 
4
Human Services shall publish on the website of the De-
5
partment of Health and Human Services an action plan 
6
describing actions the Food and Drug Administration in-
7
tends to take during the 5-year period following publica-
8
tion of the plan with respect to program enhancements, 
9
policy development, regulatory science initiatives, and 
10
other appropriate initiatives to— 
11
(1) foster the development of safe and effective 
12
drugs that improve or extend, or both, the lives of 
13
people living with amyotrophic lateral sclerosis and 
14
other rare neurodegenerative diseases as quickly as 
15
possible; and 
16
(2) facilitate access to investigational drugs for 
17
amyotrophic 
lateral 
sclerosis 
and 
other 
rare 
18
neurodegenerative diseases. 
19
(b) CONTENTS.—The initial action plan published 
20
under subsection (a) shall— 
21
(1) identify appropriate representation from 
22
within the Food and Drug Administration to be re-
23
sponsible for implementation of such action plan; 
24
(2) include elements to facilitate— 
25
22:46 Jun 23, 2021
H3537
10 
•HR 3537 IH
(A) interactions and collaboration between 
1
the Food and Drug Administration, including 
2
the review centers thereof, and stakeholders in-
3
cluding patients, sponsors, and the external bio-
4
medical research community; 
5
(B) consideration of cross-cutting clinical 
6
and regulatory policy issues, including consist-
7
ency of regulatory advice and decision making; 
8
(C) identification of key regulatory science 
9
and policy issues critical to advancing develop-
10
ment of safe and effective drugs; and 
11
(D) enhancement of collaboration and en-
12
gagement by staff of the relevant centers of the 
13
Food and Drug Administration and other rel-
14
evant offices of the Food and Drug Administra-
15
tion with other operating divisions within the 
16
Department of Health and Human Services, the 
17
Partnership, and the broader neurodegenerative 
18
disease community; and 
19
(3) be subject to revision, as determined appro-
20
priate by the Secretary of Health and Human Serv-
21
ices. 
22
20:54 Jul 05, 2021
H3537
11 
•HR 3537 IH
SEC. 5. FDA RARE NEURODEGENERATIVE DISEASE GRANT 
1
PROGRAM. 
2
The Secretary of Health and Human Services shall 
3
use funds made available under section 6 to award grants 
4
and contracts to public and private entities to cover the 
5
costs of research on, and development of interventions in-
6
tended to prevent, diagnose, mitigate, treat, or cure, 
7
amyotrophic lateral sclerosis and other rare life-threat-
8
ening or severely debilitating neurodegenerative diseases 
9
in adults and children, including costs incurred with re-
10
spect to the development and critical evaluation of tools, 
11
methods, and processes— 
12
(1) to characterize such neurodegenerative dis-
13
eases and their natural history; 
14
(2) to identify molecular targets for such 
15
neurodegenerative diseases; and 
16
(3) to increase efficiency and productivity of 
17
clinical development of therapies, including advanc-
18
ing rational therapeutic development and working to 
19
establish new or leverage existing clinical trial net-
20
works. 
21
SEC. 6. AUTHORIZATION OF APPROPRIATIONS. 
22
For purposes of carrying out this Act, there are au-
23
thorized to be appropriated $100,000,000 for each of fis-
24
cal years 2022 through 2026. 
25
Æ 
22:46 Jun 23, 2021
H3537
